Related Experiment Video

Updated: Jul 20, 2026

Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy
08:34

Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy

Published on: September 25, 2017

Regression of left ventricular hypertrophy in children with antihypertensive therapy

Prema Ramaswamy1, Irene D Lytrivi, Chikku Paul

  • 1Division of Pediatric Cardiology, Maimonides Infants and Children's Hospital, 977 48th Street, Brooklyn, NY 11219, USA. pramaswamy@maimonidesmed.org

Pediatric Nephrology (Berlin, Germany)
|September 7, 2006
PubMed

Insights

Left ventricular hypertrophy (LVH) in children can regress with antihypertensive medications. This highlights the need for further pediatric studies on hypertension-induced LVH treatment and outcomes.

Area of Science:

  • Cardiology
  • Pediatrics
  • Hypertension Research

Background:

  • Left ventricular hypertrophy (LVH) is a known complication of hypertension in adults, with established regression following pharmacologic treatment.
  • While LVH also occurs in pediatric hypertension, its regression in this population is less understood.
  • Research on pediatric LVH regression is crucial due to the increasing prevalence of childhood hypertension.

Observation:

  • This report details three pediatric cases of hypertension-induced LVH.
  • The cases demonstrate the occurrence of LVH as a complication of hypertension in children.
  • These observations underscore the potential for LVH in pediatric hypertension.

Findings:

  • Successful regression of LVH was observed in all three pediatric cases following treatment with antihypertensive medications.
  • Pharmacologic intervention proved effective in reversing hypertension-induced cardiac changes in the pediatric subjects.
  • The findings suggest that antihypertensive therapy can mitigate LVH in hypertensive children.

Implications:

  • The findings indicate a need for larger, prospective studies to confirm LVH regression in pediatric hypertension.
  • Further research should focus on the incidence, natural history, and optimal treatment strategies for LVH in children.
  • Establishing effective treatment protocols for pediatric hypertension-induced LVH is essential for long-term cardiovascular health.

More Related Videos

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents07:26

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

Published on: July 14, 2021

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

Related Concept Videos

Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...